MedWatch

Antiviral UCPH spinout powers up after September's big capital injection

The biotech firm Synklino, which is developing an antiviral treatment and whose owner group was joined by two funds last month, has hired two experienced biotech profiles to raise around EUR 30m in the spring and bring the firm's drug through phase I.

Synklino's CEO and Co-Founder Thomas Kledal | Foto: Synklino / PR

The Copenhagen-based firm Synklino, which is developing an antiviral drug, received a capital injection worth DKK 13m (USD 2.0m) in September from the newly established life science fund Eir Ventures and the Danish Growth fund – and the company has wasted no time putting this money to use.

The firm, which was established in the summer of 2017 by the three researchers Thomas Kledal, Mette Rosenkilde and Mads G. Jeppesen as a University of Copenhagen (UCPH) and Technical University of Denmark (DTU) spinout, is expanding its staff group with two experienced biotech profiles taking up the positions of Chief Financial Officer and Chief Medical Officer, respectively.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Biontech-direktører: Derfor måtte Afrika vente på coronavacciner

Tyske Biontech vil bruge de mange corona-milliarder på at hjælpe lande i Afrika med at komme både coronavirus, malaria og turberkulose til livs, men alligevel stod kontinentet langt nede i køen, da de første coronavacciner skulle distribueres. MedWatch har spurgt hvorfor.

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier